Official UK procurement notice
Branded and Biosimilar Ophthalmology
Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) (NHS & healthcare)
What is being bought4 lots · detail below
Published requirement descriptionSupply of Branded and Biosimilar Ophthalmology to NHS Scotland.
CPV: Pharmaceutical products
How this framework works
From the published notice- Places
- up to 6 suppliers · 5 bids on the busiest of 3 lots (0.8 per place) · 7 appointed (full)
Lots and requirements (4)Procurement structure
4 lots · all with a published value · evaluation weights differ by lotLot #1Aflibercept (Eylea®)CancelledRenewalPublished value£89,785,600
Supply of Aflibercept (Eylea®) vials and Pre-filled Syringes to NHS Scotland. The Authority has awarded this Framework as a single supplier framework to a single Framework Participant.
Lot #2Aflibercept BiosimilarCancelledRenewalPublished value£1
Supply of Aflibercept Biosimilar vials and Pre-filled Syringes to NHS Scotland. The Authority has awarded this Framework as an unranked multi- supplier framework to five (5) Framework Participants.
Lot #3Ranibizumab vials and Pre-filled SyringesCancelledRenewalPublished value£5,056,988
Supply of Ranibizumab Branded and Biosimilar vials and Pre-filled Syringes to NHS Scotland. The Authority has awarded this Framework as an unranked multi- supplier framework to two (2) Framework Participants.
Lot #4Faricimab (Vabysmo®)CancelledRenewalPublished value£51,736,628
Supply of Faricimab vials and Pre-filled Syringes to NHS Scotland. The Authority has not awarded this Framework to any suppliers.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Lots publish different evaluation splits; there is no single procedure weighting.
| Lot | Quality | Price | Split |
|---|---|---|---|
| 1 · Aflibercept (Eylea®) | 5% | 95% | |
| 2 · Aflibercept Biosimilar | 5% | 95% | |
| 3 · Ranibizumab vials and Pre-filled Syringes | 5% | 95% | |
| 4 · Faricimab (Vabysmo®) | 5% | 95% |
- Suitability
Economic operators may be excluded from this competition if they are in breach of any situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015
- Technical & professional ability
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB, or PLPI number) that has been approved by the MHRA for all tendered Medicines at the start date of the Framework Agreement.
(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.
(d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.
(e) Potential Framework Participants must be able to demonstrate that all devices tendered and associated ancillaries under this Framework Agreement comply with Medical Devices Regulations 2002 (SI 2002 No 618, as amended) (UK MDR 2002) and have an appropriate declaration of conformity and display a valid CE, CE UKNI or UKCA mark.
Minimum: (a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB, PLPI number) that has been approved by the MHRA for all tendered Medicines at the start date of the Framework Agreement should be included in the Qualification Envelope of the ITT under the…
- Price carries 95 points on every lot: a 10% discount moves about 9.5 points.
- “Branded and Biosimilar Ophthalmology” is a framework: the contest is a place on its panel, up to 6 suppliers, not a single contract.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 6 Aug 2025, 12:10 BST
- Last source update
- 24 Nov 2025, 16:57 GMT
- Award evaluation window
- 5 Sept 2025 – …
- Authority reference
NP33925- FTS notice number
2025/S 000-076640- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-058262Find a Tender
- Electronic trading
- e-invoicing allowed · electronic ordering · electronic payment
- Review procedure
Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:
An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.
The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are
limited to the award of damages.
Publisher note: The estimated value(s) referred to in Section II.1.5 cover(s) the twelve (12) month contract duration and the thirty six (36) month extension period of the framework agreement. (SC Ref:812873)
How it was run
Official notice- Appointment period ends
- 5 Sept 2025, 12:00 BST
- Submission channel
- {"electronicSubmission"}
- Accepted languages
- en
- Bid validity
- 90 days from the deadline
- Bids opened
- 5 Sept 2025, 12:00 BST
Timeline
5 Sept 2025 → 24 Nov 2025 · 3 dates- Admission / appointment period endsperiod end, not a bid countdown5 Sept 2025, 12:00 BST
- Bids opened5 Sept 2025, 12:00 BST
- Notice published332 days ago24 Nov 2025, 16:57 GMT
Notice history
1 event · 2 releases on Find a Tender- Status changed to complete24 Nov 2025, 16:57 GMT
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast3 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
Aflibercept (Eylea®)
- Signed
- 30 Oct 2025
- Value
- £9,272,932
- Status
- active
Aflibercept Biosimilar
- Signed
- 30 Oct 2025
- Value
- £8,685,992
- Status
- active
Ranibizumab vials and Pre-filled Syringes
- Signed
- 30 Oct 2025
- Value
- £2,712,160
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · Aflibercept (Eylea®) | 1bids · 1 electronic · 1 from abroad | 1 | — | — |
| 2 · Aflibercept Biosimilar | 5bids · 5 electronic · 5 from abroad | 4 | — | — |
| 3 · Ranibizumab vials and Pre-filled Syringes | 3bids · 3 electronic · 3 from abroad | 1 | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Sheriff Court HouseReview body
Framework contractors & participating bidders
7 commercial parties on the notice- Bayer PlcFramework contractor
- Biogen Idec LtdFramework contractor
- Celltrion Healthcare United Kingdom LimitedFramework contractor
- MD BiologicsFramework contractor
- Mercury Pharmaceuticals LimitedFramework contractor
- SandozFramework contractor
- Teva UK LtdFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.